TIL News and Press, Instil Bio Inc. From 03/31/23

2023-03-31 09:19:44 ET Instil Bio press release ( NASDAQ: TIL ): Q4 GAAP EPS of -$0.41 in-line. As of December 31, 2022, Instil had $260.9 million in total cash and cash equivalents and marketable securities, comprised of $43.7 million in cash and cash equiv...

Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 DALLAS, March 31, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil&#x...

Instil Bio ( NASDAQ: TIL ) said it would extend reduction-in-force to a team of about 15 employees in the U.S. to lead global business operations, including the consolidation of clinical manufacturing and trial operations of its CoStAR-TIL to its active Manchester, U.K. operations. ...

Company anticipates cash resources to provide runway beyond 2026 Initial clinical data from the ITIL-306 program expected in 2023 Instil is consolidating manufacturing and Phase 1 clinical trial of CoStAR-TIL™ to its operations in Manchester, U.K. Instil to extend...

Penny Stocks, News, & Market Momentum This Week This is the first full week of the New Year and one that many investors will be focused on. Not only will we see Federal Reserve Chair Jerome Powell’s first major speech of the year, but there’s also no time wasted for the firs...

Phase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause Initial data readout for ITIL-306 expected in 2023 With recent reprioritization of clinical programs and corporate restructuring, company expects cash runway into 2025, excluding p...

NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against PROG Holdings, Inc. (NYSE: PRG), Fox Corporation (NASDAQ: FOX, FOXA), Instil Bio, Inc. (NASDAQ: TIL), and Twist Bioscience Co...

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Instil Bio, Inc. (NASDAQ:TIL) (“Instil” or the “Company”). The investigations concern whether certain of the Instil’s officers and directors breached their...

Instil Bio ( NASDAQ: TIL ) announced an approximately 60% reduction in its U.S. headcount on Thursday as cancer-focused biotech undertook a major reprioritization of its pipeline in a pivot from a registration-driven company to a development-stage company. The company shares fell 1...

Discontinuing unmodified TIL programs, including DELTA-1 and DELTA-2 trials of ITIL-168 Prioritizing CoStAR-TIL programs for clinical development, including ITIL-306 in Phase 1 trial for NSCLC, ovarian, and renal cell carcinoma Reducing U.S. headcount by approximately 60% ...